CLEC4C (Myc-DDK-tagged)-Human C-type lectin domain family 4, member C (CLEC4C), transcript variant 2
| Type | Human Tagged ORF Clone |
| Tag | Myc-DDK |
| Vector | pCMV6-Entry |
Products
CLEC4C (Myc-DDK-tagged)-Human C-type lectin domain family 4, member C (CLEC4C), transcript variant 1
| Type | Human Tagged ORF Clone |
| Tag | Myc-DDK |
| Vector | pCMV6-Entry |
- TrueORF®
CLEC4C - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated.
| Format | 2 gRNA vectors, 1 linear donor |
| Donor DNA | EF1a-GFP-P2A-Puro |
Transient overexpression lysate of C-type lectin domain family 4, member C (CLEC4C), transcript variant 2
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
CLEC4C HEK293T cell transient overexpression lysate (as WB positive control)
| Tag | C-Myc/DDK |
| Expression Host | HEK293T |
CLEC4C CRISPRa kit - CRISPR gene activation of human C-type lectin domain family 4 member C
| Format | 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug) |
Transient overexpression of CLEC4C, transcript variant 2, in HEK293T cells, FFPE control for IHC, ICC and ISH staining, 25 slides per pack
CLEC4C - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
qSTAR qPCR primer pairs against Homo sapiens gene CLEC4C
CLEC4C - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Anti-CLEC4C Rabbit Polyclonal Antibody
| Applications | IHC |
| Reactivities | Human |
Anti-CLEC4C Rabbit Polyclonal Antibody
| Applications | IHC |
| Reactivities | Human |
Anti-CLEC4C Reference Antibody (LFB patent anti-BDCA-2)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human |
Anti-CLEC4C Reference Antibody (BIIB059)
| Applications | Animal Model, ELISA, FACS, FN, Kinetics |
| Reactivities | Human, Cynomolgus |
Anti-Hu CD303 Purified
| Applications | ELISA, FC, ICC, IHC |
| Reactivities | Human |
